Business Wire

Mavenir Launches Open RAN Intelligent Controller (O-RIC) Offering Enabling Service Differentiation and Network Resource Optimization

10.2.2023 17:00:00 EET | Business Wire | Press release

Share

Mavenir, the Network Software Provider building the future of networks with cloud-native solutions that run on any cloud, today announced the availability of its O-RAN alliance Radio Access Network Intelligent Controller (RIC), a next-generation network intelligence offering for Open RAN. Mavenir O-RIC enables the creation of differentiated services through open APIs, which enable intelligent closed-loop end-to-end network tuning to optimize network performance, increase cost efficiency and maximize the user experience. Mavenir’s O-RIC offers Network Intelligence as a Service (NIaaS) that provides deep, fine-grained insights about the network and enables building solutions with advanced state of art intelligence. Open RAN networks can also now generate new class-of-service revenue streams by adaptively reacting in near-real time to dynamic changes in network, traffic, and load patterns. Mavenir’s O-RIC is currently in deployment with two, tier one Communications Service Providers (CSPs).

Traditional RAN networks currently use area wide Self-Organizing Network (SON) models for exercising Radio Resource Management (RRM) and configuration management optimization decisions at a per-cell level. They rely on single control loop, leverage key performance indicators (KPIs) and analytics for such control decisions at non-real time (Non-RT) granularities.

Mavenir’s O-RIC surpasses the capabilities of SON with two control loops:

  • Non-RT O-RIC — Typically deployed in a centralized cloud, it builds advanced Machine Learning (ML) algorithms using long-term RAN data to define dynamic and adaptive policies to control and optimize network performance and configuration management decisions. Non-RT RIC can also be used in existing legacy networks, adding another performance layer through ML for policy control.
  • Near-real time (Near-RT) O-RIC — Deployed at or towards the edge, it uses a low latency control loop that optimizes RAN activity at both the cell and individual user equipment (UE) level by hosting trained Artificial Intelligence (AI) and ML applications to infer and control Open RAN elements in near-RT. The near-RT O-RIC intelligently optimizes UE-level control-plane call processing and user-plane data transfer decisions. This level of granularity is not available in SON.

Mavenir’s O-RIC is a business results tool, that enables intent-based decisions by setting granular performance targets—at the cell or even individual UE level—to generate business outcomes, such as the generation of additional revenue (enabling an SLA that generates a premium service), the reduction in network cost through the optimization of resources (energy savings, spectral efficiency, etc.), or the improvement of the end user experience (by improving throughput, reducing latency and connection drops, and expanding coverage). The NIaaS signature framework of Mavenir’s RIC accomplishes this goal by offering fine-grained predictive intelligence and advanced analytics about the RAN to third party applications (rApps and xApps), integrated with Mavenir’s O-RIC, towards optimizing the network performance.

Mavenir’s O-RIC shifts control from the vendor ecosystem to the operator by delivering an Open API framework that allows the implementation of standards-based rApps and xApps for different business outcomes, such as energy savings, traffic steering, massive MIMO optimization, spectral efficiency improvements, and RAN slice assurance. Proprietary radio access solutions limit the choice to what their vendor has to offer and open up the network to fine-grained per user data-driven optimization. With Mavenir’s RIC, applications can be developed by an in-house team or purchased in an "app store" from any Open RAN compliant third party.

"Creating real business value for next-generation Open RAN networks requires deep telco domain expertise and a disruptive approach to network intelligence," said Brandon Larson, SVP & GM of the Multimedia Business Unit at Mavenir. "As a pioneer in cloud-native solutions at a massive scale, Mavenir is leading the way with award-winning Open vRAN solutions, layered with O-RIC AI and ML algorithms and applications, which create operator customizable business outcomes based on target objectives to solve unique business problems and give control of the network back to the CSP."

Mavenir's O-RIC offers unparalleled benefits in terms of (i) Network performance, (ii) User Experience, (iii) Reduced TCO, (iv) Simplified cloud-native deployments, (v) new revenue sources, etc.

For more information visit the Mavenir Open RAN Intelligent Controller page.

Mavenir is exhibiting at Mobile World Congress 2023 in Barcelona, Spain at the Fira Gran Via in Hall 2, stand 2H60. Click here to find out more.

About Mavenir:

Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world's subscribers. www.mavenir.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PR@mavenir.com
Maryvonne Tubb (US)
Emmanuela Spiteri (EMEA)

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release

Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release

Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory

Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye